ABBVIE INC. overview

AbbVie to Present at the Bank of America Securities Healthcare Conference PR Newswire NORTH CHICAGO, Ill., May 6, 2024 NORTH CHICAGO, Ill. , May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024 . Robert A. Michael , president and chief operating officer, Scott T. Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and...

AbbVie Reports First-Quarter 2024 Financial Results PR Newswire NORTH CHICAGO, Ill., April 26, 2024 Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31 , a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $12.310 Billion , an Increase of 0.7 Percent on a Reported Basis and 1.6 Percent on an Operational...

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study PR Newswire NORTH CHICAGO, Ill., April 25, 2024 Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 16 1 LEVEL UP, a Phase 3b /4 head-to-head study, compared upadacitinib to...

Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands PR Newswire IRVINE, Calif., April 23, 2024 Consumers Can Apply for a Chance to Be Featured in Upcoming Campaigns for BOTOX ® Cosmetic, the JUVÉDERM ® Collection of Fillers, and Allē, the Allergan Aesthetics Loyalty Rewards Program IRVINE, Calif. , April 23, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to...

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis PR Newswire NORTH CHICAGO, Ill., April 18, 2024 − Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ ® ; 15 mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through week 52 compared to 29 percent of patients receiving placebo with a 52-week steroid...

Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie PR Newswire MILWAUKEE, April 16, 2024 MILWAUKEE , April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ: LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie . Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at...

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine PR Newswire NORTH CHICAGO, Ill., April 12, 2024 - Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine - Seventy percent of subjects achieved ≥50% reduction in monthly migraine days at Weeks 13-16 and this was consistent during the 48...

SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne PR Newswire IRVINE, Calif., April 9, 2024 From the makers of BOTOX ® Cosmetic, two new SkinMedica ® acne products help address skin blemishes and can be combined with in-office DiamondGlow ® IRVINE, Calif. , April 9, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the launch of two new products from SkinMedica ® by the makers of BOTOX ® Cosmetic. The SkinMedica ® Acne...